Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme

Journal of Neuroscience Research

Volumn 92, Issue 9, 2014, Pages 1178-1186

  Liu, Shuyu ^a   Liu, Junjun ^a   Miura, Yukie ^a   Tanabe, Chiaki ^a   Maeda, Tomoji ^a   Terayama, Yasuo ^a   Turner, Anthony J ^b   Zou, Kun ^a   Komano, Hiroto ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid protein; Angiotensin converting enzyme; Angiotensin converting enzyme 2

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 43; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); AMYLOID BETA-PROTEIN (1-43); DX600 PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PURIFICATION; FEMALE; HUMAN; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; C57BL MOUSE; CONFOCAL MICROSCOPY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; SERUM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; PEPTIDE FRAGMENTS; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; SERUM;

EID: 84904253583     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23404     Document Type: Article

References (30)

1. Blennow K, de Leon MJ, Zetterberg H. 2006. Alzheimer's disease. Lancet 368:387-403.
2. Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, De Strooper B, Buee L. 2012. Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci 32:7852-7861.
3. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. 2002. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:822-828.
4. Danilczyk U, Penninger JM. 2006. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98:463-471.
5. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:E1-9.
6. Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ. 2003. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 42:13185-13192.
7. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112.
8. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. 2004. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631-637.
9. Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanyal I, Parry T, Kent R, Enright J, Wu QL, Conley G, DeOliveira D, Morganelli L, Ducar M, Wescott CR, Ladner RC. 2003. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 278:15532-15540.
10. Iizuka T, Shoji M, Harigaya Y, Kawarabayashi T, Watanabe M, Kanai M, Hirai S. 1995. Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Brain Res 702:275-278.
11. Katovich MJ, Grobe JL, Huentelman M, Raizada MK. 2005. Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Exp Physiol 90:299-305.
12. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. 2007. Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27:627-633.
13. Lai ZW, Hanchapola I, Steer DL, Smith AI. 2011. Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. Biochemistry 50:5182-5194.
14. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. 2005. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280:30113-30119.
15. Masters CL, Selkoe DJ. 2012. Biochemistry of amyloid beta-protein and amyloid deposits in alzheimer disease. Cold Spring Harbor Perspect Med 2:a006262.
16. Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, Nakayama T, Ihara Y, Takeda M. 2013. gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave Abeta42 and Abeta43. Cell Rep 3:42-51.
17. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. 2010. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:529-538.
18. Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M. 2012. recombinant expression and characterization of human and murine ACE2: species-specific activation of the alternative renin-angiotensin-system. Int J Hypertens 2012:428950.
19. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y, Saido TC. 2011. Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci 14:1023-1032.
20. Selkoe DJ. 2011. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17:1060-1065.
21. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875.
22. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. 2000. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238-33243.
23. Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO. 2009. Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110:697-706.
24. Xia H, Lazartigues E. 2008. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem 107:1482-1494.
25. Xia H, Feng Y, Obr TD, Hickman PJ, Lazartigues E. 2009. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension 53:210-216.
26. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. 2010. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122:717-728.
27. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M. 2003. Amyloid-beta protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87:609-619.
28. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagisawa K, Michikawa M. 2007. Angiotensin-converting enzyme converts amyloid-beta protein 1-42 (Abeta[1-42]) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 27:8628-8635.
29. Zou K, Maeda T, Watanabe A, Liu J, Liu S, Oba R, Satoh Y, Komano H, Michikawa M. 2009. Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem 284:31914-31920.
30. Zou K, Liu J, Watanabe A, Hiraga S, Liu S, Tanabe C, Maeda T, Terayama Y, Takahashi S, Michikawa M, Komano H. 2013. Abeta43 is the earliest-depositing Abeta species in APP transgenic mouse brain and is converted to Abeta41 by two active domains of ACE. Am J Pathol 182:2322-2331.